Presentation is loading. Please wait.

Presentation is loading. Please wait.

This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.

Similar presentations


Presentation on theme: "This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive."— Presentation transcript:

1 This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA) Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD

2 This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Aim – Describe COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. Relevance – With improved survivability following cancer treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.

3 This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Method COMP-VA is designed to be administered on chemo- therapy treatment unit just before treatment (chairside). – Uses portable ototoxicity identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.

4 This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Clinical Objectives Pretreatment ototoxicity risk assessment. Behavioral screening for early hearing changes. Screening for outer hair cell dysfunction. Nonbehavioral screening for early hearing changes. Screen failure follow-up testing. Screening for tinnitus. Patient and provider education about ototoxic- induced hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.

5 This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Conclusion Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the- minute estimates of ototoxicity before patient’s next treatment. – This allows for timely consideration of treatment changes. Program encourages efficient communication and team relationships between audiology and oncology.


Download ppt "This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive."

Similar presentations


Ads by Google